The shares of Fluidigm Corporation (NASDAQ:FLDM) has been pegged with a rating of Neutral by Janney in its latest research note that was published on November 06, 2019. Janney wasn’t the only research firm that published a report of Fluidigm Corporation, with other equities research analysts also giving their opinion on the stock. UBS advised investors in its research note published on October 18, 2019, to Buy the FLDM stock while also putting a $7 price target. The stock had earned Neutral rating from UBS Markets when it published its report on March 15, 2019. That day the UBS set price target on the stock to $14. Piper Jaffray was of a view that FLDM is Overweight in its latest report on November 02, 2018. Mizuho thinks that FLDM is worth Buy rating. This was contained in the firm’s report on August 05, 2016 in which the stock’s price target was also moved to 12.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 2 believe it has the potential for further growth, thus rating it as Hold while 3 advised investors to purchase the stock. The consensus currently stands at a Overweight while its average price target is $7.20. The price of the stock the last time has raised by 58.12% from its 52-Week high price while it is -87.06% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 38.92.
The shares of the company dipped by -9.76% during the trading session on Tuesday, reaching a low of $1.81 while ending the day at $1.85. During the trading session, a total of 765653.0 shares were traded which represents a -1.51% decline from the average session volume which is 754250.0 shares. FLDM had ended its last session trading at $2.05. Fluidigm Corporation debt-to-equity ratio currently stands at 0.35, while its quick ratio hovers at 2.50 FLDM 52-week low price stands at $1.17 while its 52-week high price is $14.30.
The company in its last quarterly report recorded -$0.07 earnings per share which is above the predicted by most analysts. The Fluidigm Corporation generated 21.66 million in revenue during the last quarter. In the second quarter last year, the firm recorded -$0.14 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -157.14%. Fluidigm Corporation has the potential to record -0.44 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Morgan Stanley published a research note on April 02, 2020 where it informed investors and clients that Elanco Animal Health Incorporated (NYSE:ELAN) is now rated as Equal-Weight. Even though the stock has been trading at $21.98/share, analysts expect it to surge by 3.50% to reach $31.25/share. It started the day trading at $23.30 and traded between $22.075 and $22.75 throughout the trading session.
A look at its technical shows that ELAN’s 50-day SMA is 25.91 while its 200-day SMA stands at 28.17. The stock has a high of $35.46 for the year while the low is $15.17. The stock, however, witnessed a rise in its short on 03/13/20. Compared to previous close which recorded 12.92 M shorted shares, the short percentage went higher by 9.21%, as 14.11M FLDM shares were shorted. At the moment, only 3.55% of Elanco Animal Health Incorporated shares were sold short. The company’s P/E ratio currently sits at 122.97, while the P/B ratio is 1.53. The company’s average trading volume currently stands at 6.62M shares, which means that the short-interest ratio is just 2.13 days. Over the past seven days, the company moved, with its shift of 1.61%. Looking further, the stock has dropped -20.76% over the past 90 days while it lost -14.60% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The T. Rowe Price Associates, Inc. (I… bought more ELAN shares, increasing its portfolio by 23.83% during the last quarter. This move now sees The T. Rowe Price Associates, Inc. (I… purchasing 7,957,220 shares in the last quarter, thus it now holds 41,341,877 shares of ELAN, with a total valuation of $925,644,626. The Vanguard Group, Inc. meanwhile bought more ELAN shares in the recently filed quarter, changing its stake to $754,972,843 worth of shares.
Similarly, Wellington Management Co. LLP decreased its Elanco Animal Health Incorporated shares by 3.56% during the recently filed quarter. After selling 30,932,315 shares in the last quarter, the firm now controls -1,141,950 shares of Elanco Animal Health Incorporated which are valued at $692,574,533. In the same vein, PRIMECAP Management Co. decreased its Elanco Animal Health Incorporated shares by during the most recent reported quarter. The firm bought 152,983 shares during the quarter which decreased its stakes to 30,598,365 shares and is now valued at $685,097,392. Following these latest developments, around 0.30% of Elanco Animal Health Incorporated stocks are owned by institutional investors and hedge funds.